SQI Diagnostics Expanding Its Proprietary Rapid Diagnostic Testing Portfolio Targeting Organ Transplant, Autoimmune Disease and Serological Testing

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

September 9, 2020

SQI Diagnostics, Inc., is a precision medicine company that discovers, develops, manufactures, and commercializes innovative rapid diagnostic testing for healthcare professionals, patients, and consumers worldwide.

Today they announced it is expanding its proprietary rapid diagnostic testing portfolio targeting organ transplant, autoimmune disease, and serological testing.

SQI Diagnostics, Inc. CEO Mr. Robert L. Chioini stated, “Within our organ transplant, autoimmune disease, and serological testing business units we have multiple products in clinical development, and we believe these advanced tests have the potential to offer patients and consumers significant benefit once they receive regulatory approval. Our COVID-19 At-home Antibody Test Kit and our COVID-19 Patient Triage Test are currently a top priority. We will provide more detail on our novel diagnostics, their clinical progress, and our commercialization efforts shortly.”

Mr. Chioini further stated, “Rapid diagnostic testing that is accurate and widely available is now more important than ever. It is intended that SQI’s direct-to-consumer diagnostic test kits will provide access to convenient, reliable, medical tests for use at home and empower people to improve their health outcomes, while our patient-based diagnostics will enable clinicians to provide fast effective treatment in the healthcare setting. SQI’s unique strategy of merging innovative diagnostics with differentiated health management services will enable us to provide comprehensive support for healthcare professionals, patients, and consumers across the globe.”

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.